Literature DB >> 35368077

cSurvival: a web resource for biomarker interactions in cancer outcomes and in cell lines.

Xuanjin Cheng1,2,3, Yongxing Liu1,2,3, Jiahe Wang1,2,3, Yujie Chen1,2,3, Andrew Gordon Robertson4, Xuekui Zhang5, Steven J M Jones3,4, Stefan Taubert1,2,3.   

Abstract

Survival analysis is a technique for identifying prognostic biomarkers and genetic vulnerabilities in cancer studies. Large-scale consortium-based projects have profiled >11 000 adult and >4000 pediatric tumor cases with clinical outcomes and multiomics approaches. This provides a resource for investigating molecular-level cancer etiologies using clinical correlations. Although cancers often arise from multiple genetic vulnerabilities and have deregulated gene sets (GSs), existing survival analysis protocols can report only on individual genes. Additionally, there is no systematic method to connect clinical outcomes with experimental (cell line) data. To address these gaps, we developed cSurvival (https://tau.cmmt.ubc.ca/cSurvival). cSurvival provides a user-adjustable analytical pipeline with a curated, integrated database and offers three main advances: (i) joint analysis with two genomic predictors to identify interacting biomarkers, including new algorithms to identify optimal cutoffs for two continuous predictors; (ii) survival analysis not only at the gene, but also the GS level; and (iii) integration of clinical and experimental cell line studies to generate synergistic biological insights. To demonstrate these advances, we report three case studies. We confirmed findings of autophagy-dependent survival in colorectal cancers and of synergistic negative effects between high expression of SLC7A11 and SLC2A1 on outcomes in several cancers. We further used cSurvival to identify high expression of the Nrf2-antioxidant response element pathway as a main indicator for lung cancer prognosis and for cellular resistance to oxidative stress-inducing drugs. Altogether, these analyses demonstrate cSurvival's ability to support biomarker prognosis and interaction analysis via gene- and GS-level approaches and to integrate clinical and experimental biomedical studies.
© The Author(s) 2022. Published by Oxford University Press.

Entities:  

Keywords:  DepMap; TARGET; TCGA; biomarker; genetic interaction; survival analysis

Mesh:

Substances:

Year:  2022        PMID: 35368077      PMCID: PMC9116376          DOI: 10.1093/bib/bbac090

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   13.994


  71 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  GSCALite: a web server for gene set cancer analysis.

Authors:  Chun-Jie Liu; Fei-Fei Hu; Meng-Xuan Xia; Leng Han; Qiong Zhang; An-Yuan Guo
Journal:  Bioinformatics       Date:  2018-11-01       Impact factor: 6.937

3.  TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages.

Authors:  Tiago C Silva; Antonio Colaprico; Catharina Olsen; Fulvio D'Angelo; Gianluca Bontempi; Michele Ceccarelli; Houtan Noushmehr
Journal:  F1000Res       Date:  2016-06-29

4.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

5.  Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.

Authors:  Xiao-Jun Wang; Zheng Sun; Nicole F Villeneuve; Shirley Zhang; Fei Zhao; Yanjie Li; Weimin Chen; Xiaofang Yi; Wenxin Zheng; Georg T Wondrak; Pak Kin Wong; Donna D Zhang
Journal:  Carcinogenesis       Date:  2008-04-15       Impact factor: 4.944

6.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.

Authors:  Kyle Ellrott; Matthew H Bailey; Gordon Saksena; Kyle R Covington; Cyriac Kandoth; Chip Stewart; Julian Hess; Singer Ma; Kami E Chiotti; Michael McLellan; Heidi J Sofia; Carolyn Hutter; Gad Getz; David Wheeler; Li Ding
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

7.  New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx.

Authors:  Mohamed Mounir; Marta Lucchetta; Tiago C Silva; Catharina Olsen; Gianluca Bontempi; Xi Chen; Houtan Noushmehr; Antonio Colaprico; Elena Papaleo
Journal:  PLoS Comput Biol       Date:  2019-03-05       Impact factor: 4.475

8.  PrognoScan: a new database for meta-analysis of the prognostic value of genes.

Authors:  Hideaki Mizuno; Kunio Kitada; Kenta Nakai; Akinori Sarai
Journal:  BMC Med Genomics       Date:  2009-04-24       Impact factor: 3.063

Review 9.  Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit.

Authors:  M J Bradburn; T G Clark; S B Love; D G Altman
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.